BUND FINANCE

BUND FINANCE › Stocks › ABBV

AbbVie Inc. (ABBV)

NYSE · Stock price, chart and technical analysis

US$285.96-6.86 (-2.34%)

Data from Financial Modeling Prep · Nov 18, 2026, 3:59 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$292.82
OpenUS$290.00
Day rangeUS$284.91 – US$292.44
52-week rangeUS$190.75 – US$302.93
Market capUS$505.47B
Volume4.73M
50-day averageUS$277.15
200-day averageUS$241.48
Beta0.28
Last dividend per shareUS$6.92

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$56.2BUS$58.1BUS$54.3BUS$56.3BUS$61.2B
Net incomeUS$11.5BUS$11.8BUS$4.9BUS$4.3BUS$4.2B
EPS (diluted)6.456.632.722.392.37
Gross margin69.0%70.0%62.4%70.0%70.2%
Operating margin31.9%31.2%23.5%16.2%24.7%
Net margin20.5%20.4%9.0%7.6%6.9%
Free cash flowUS$22.0BUS$24.2BUS$22.1BUS$17.8BUS$17.8B
Total debtUS$77.6BUS$64.2BUS$60.1BUS$67.8BUS$69.1B
CashUS$9.7BUS$9.2BUS$12.8BUS$5.5BUS$5.2B

Compound annual growth: revenue 2.1% · net income -22.2% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E49.1x54.5x27.1x
EV / EBITDA22.9x19.5x16.5x
Operating margin35.2%—3.6%
Net margin15.7%—-0.0%
Debt / equity——0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About AbbVie Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
CEORobert A. Michael
Employees57,000
IPO date2013-01-02

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) …

www.abbvie.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice